Results 221 to 230 of about 710,185 (341)
Pulmonary arterial hypertension with cardiopulmonary comorbidities: is it a unique phenotype? [PDF]
Zhang M +21 more
europepmc +1 more source
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr +18 more
wiley +1 more source
Exploring the interplay between mitochondria and endoplasmic reticulum in pulmonary arterial hypertension. [PDF]
Liao Z, He Y.
europepmc +1 more source
Cilostazol Therapy Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rat Model
Li‐Teh Chang +7 more
openalex +2 more sources
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman +13 more
wiley +1 more source
Trends and projections of the global burden of pulmonary arterial hypertension (1990-2050): An observational trend study. [PDF]
Li Y, Bin N, Zhou J, Jiang L, Wang H.
europepmc +1 more source
Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension [PDF]
Christian Opitz +11 more
openalex +1 more source
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang +12 more
wiley +1 more source

